Business Description
Genprex Inc
NAICS : 325412
SIC : 2834
ISIN : US3724461047
Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.66 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4 | |||||
| 3-Year EPS without NRI Growth Rate | -3.4 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | -44.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 60.92 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.49 | |||||
| 9-Day RSI | 56.56 | |||||
| 14-Day RSI | 58.54 | |||||
| 6-1 Month Momentum % | -84.07 | |||||
| 12-1 Month Momentum % | -95.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.95 | |||||
| Quick Ratio | 1.95 | |||||
| Cash Ratio | 1.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.3 | |||||
| Shareholder Yield % | -211 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -291.28 | |||||
| ROA % | -209.48 | |||||
| ROIC % | -502.93 | |||||
| 3-Year ROIIC % | -1221.04 | |||||
| ROC (Joel Greenblatt) % | -328600 | |||||
| ROCE % | -292.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | -0.15 | |||||
| EV-to-EBITDA | -0.15 | |||||
| EV-to-FCF | -0.19 | |||||
| Price-to-Net-Current-Asset-Value | 2.42 | |||||
| Price-to-Net-Cash | 25.38 | |||||
| Earnings Yield (Greenblatt) % | -666.67 | |||||
| FCF Yield % | -398.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNPX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genprex Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -15.65 | ||
| Beta | 0.08 | ||
| Volatility % | 94.85 | ||
| 14-Day RSI | 58.54 | ||
| 14-Day ATR ($) | 0.457096 | ||
| 20-Day SMA ($) | 1.16276 | ||
| 12-1 Month Momentum % | -95.57 | ||
| 52-Week Range ($) | 0.2806 - 14.796 | ||
| Shares Outstanding (Mil) | 2.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genprex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genprex Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genprex Inc Frequently Asked Questions
What is Genprex Inc(GNPX)'s stock price today?
The current price of GNPX is $2.03. The 52 week high of GNPX is $14.80 and 52 week low is $0.28.
When is next earnings date of Genprex Inc(GNPX)?
The next earnings date of Genprex Inc(GNPX) is .
Does Genprex Inc(GNPX) pay dividends? If so, how much?
Genprex Inc(GNPX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers